Key result
Chemotherapy-induced peripheral neuropathy symptoms significantly impaired occupational function, with 50% of chemotherapy-treated breast cancer survivors reporting reduced ability to work at 1 month post-treatment compared to 9.1% of chemotherapy-naïve survivors.
Why the study?
Does chemotherapy-induced peripheral neuropathy impact perceived ability to work in breast cancer survivors?
Cohort (n=44)
Yes
Does chemotherapy-induced peripheral neuropathy impact perceived ability to work in breast cancer survivors?
Absolute Event Rate: 50% vs 9.1%
p-value: p=<0.05
Chemotherapy-induced peripheral neuropathy symptoms are associated with a reduced perceived ability to work at 1 month post-treatment in breast cancer survivors.
No takes yet. Share an insight, caveat, or question.
May warrant occupational assessment in breast cancer survivors with CIPN; extends prior evidence but leaves open need for prospective intervention trials.
Zanville et al. (2016) conducted a cohort in Non-metastatic breast cancer (n=44). Chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) vs. Chemotherapy-naïve breast cancer survivors was evaluated on Reduced perceived ability to work (reporting being only somewhat, a little bit, or not at all able to work) at 1 month post-treatment (p=<0.05). Chemotherapy-induced peripheral neuropathy symptoms significantly impaired occupational function, with 50% of chemotherapy-treated breast cancer survivors reporting reduced ability to work at 1 month post-treatment compared to 9.1% of chemotherapy-naïve survivors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: